Emerge Weight Loss vs Wisp
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Emerge Weight Loss
Best for patients committed to tirzepatide as their drug of choiceStarting at $299/mo
Wisp
Best for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-testedStarting at $225/mo
Side-by-Side Comparison
| Feature | Emerge Weight Loss | Wisp |
|---|---|---|
| Overall Score | ✓7.6/10 | 7.0/10 |
| Starting Price | $299/mo | ✓$225/mo |
| Editorial Rating | ✓3.8 ★ /5 | 3.5 ★ /5 |
| Features | 4 features | ✓6 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Emerge Weight Loss
Pros
- ✓Tirzepatide-focused (largest effect-size compounded GLP-1)
- ✓Wide dose range available
- ✓Physician-supervised telemedicine model
Cons
- ✗No semaglutide option — limits flexibility if tirzepatide tolerability is poor
- ✗Less brand recognition than Henry Meds, Mochi, or SkinnyRx
Wisp
Pros
- ✓Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
- ✓LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
- ✓Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing
Cons
- ✗EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
- ✗Pharmacy partners not publicly named
- ✗States served list not publicly enumerated
Our Verdict
Emerge Weight Loss edges out Wisp with a higher overall score of 7.6/10 and is particularly strong for patients committed to tirzepatide as their drug of choice. Wisp remains a solid alternative, especially if you're looking for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.